3 Key Takeaways From AbbVie's Second-Quarter Earnings
The last week of July was a busy one for investors, with several big-name companies releasing their quarterly updates for the period ending on June 30. One of those was pharma giant AbbVie (NYSE: ABBV), and the drugmaker's results were impressive.
AbbVie recorded total revenue of roughly $14 billion, 19.3% higher than the year-ago period on an operational basis. On the bottom line, the company reported earnings per share of $0.42, which was much better than the loss per share of $0.46 recorded during the second quarter of 2020. What was behind this performance? Here are three key aspects of AbbVie's success during the second quarter.
International sales of AbbVie's blockbuster rheumatoid arthritis medicine Humira have been declining since it lost patent exclusivity in Europe in 2018. Things were no different during the second quarter. International revenue from this drug came in at $811 million, a 6% year-over-year decline.
Source Fool.com
